Article
Oncology
Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph Stoll, Andrea P. Moy, Stephen W. Dusza, Allison Gordon, Elena C. Haliasos, Yelena Janjigian, Lukas Kraehenbuehl, Elizabeth A. Quigley, Paul Chapman, Mario E. Lacouture, Alina Markova
Summary: Immune checkpoint inhibitors (ICI) can effectively target cancer cells, but they may also cause immune-related cutaneous adverse events (ircAEs) in a significant number of patients. This study examined the use of dupilumab for treating ICI-associated ircAEs and found that 87% of patients responded to the treatment, with 44.1% achieving complete resolution of the adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Immunology
W. J. Mullally, F. J. Cooke, I. M. Crosbie, S. Kumar, V. E. Abernethy, E. J. Jordan, M. O'Connor, A. M. Horgan, R. Landers, J. Naidoo, P. M. Calvert
Summary: This is a case of a man in his early 50s who presented with small bowel obstruction and was found to have metastatic melanoma without a primary lesion. After receiving immunotherapy, the patient developed a series of symptoms and eventually died from immune-related thrombotic thrombocytopenic purpura (TTP).
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Bianca Gautron Moura, Camille L. Gerard, Nathalie Testart, Marian Caikovski, Alexandre Wicky, Veronica Aedo-Lopez, Gregoire Berthod, Krisztian Homicsko, John O. Prior, Clarisse Dromain, Lana E. Kandalaft, Michel A. Cuendet, Olivier Michielin
Summary: In stage IV melanoma, the combination of ipilimumab and nivolumab significantly improves outcomes but has a major financial impact on healthcare. This study analyzes the costs associated with ipilimumab-nivolumab combination, focusing on immune-related adverse events (irAE). Surprisingly, toxicity costs are insignificant compared to the total treatment costs, and patients with higher toxicity grades have lower costs and better outcomes. These findings provide important information for clinicians and healthcare organizations making treatment decisions in immunotherapy.
Article
Oncology
Olivier J. van Not, Rik J. Verheijden, Alfonsus J. M. van den Eertwegh, John B. A. G. Haanen, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Jan-Willem B. de Groot, Geke A. P. Hospers, Anna M. Kamphuis, Ellen Kapiteijn, Anne M. May, Melissa M. de Meza, Djura Piersma, Rozemarijn van Rijn, Marion A. Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Willeke A. M. Blokx, Michel J. M. Wouters, Karijn P. M. Suijkerbuijk
Summary: This cohort study found that second-line immunosuppression for immune-related adverse events (IRAEs) was associated with impaired progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy. These findings emphasize the importance of evaluating the effects of different IRAE management strategies.
Article
Oncology
Patrick Demkowicz, Renelle Pointdujour-Lim, Sofia Miguez, Yesung Lee, Bailey S. C. L. Jones, Christopher A. Barker, Marcus Bosenberg, David H. Abramson, Alexander N. Shoushtari, Harriet Kluger, Jasmine H. Francis, Mario Sznol, Mathieu F. Bakhoum
Summary: This study retrospectively analyzed clinical data of patients with metastatic uveal melanoma and found that female sex, treatment with immune checkpoint inhibitors, and the absence of liver metastasis were associated with better survival outcomes. These findings highlight the potential of immunotherapy in treating metastatic uveal melanoma.
Article
Oncology
E. Aamdal, E. Skovlund, K. D. Jacobsen, O. Straume, C. Kersten, O. Herlofsen, J. Karlsen, I Hussain, A. Amundsen, A. Dalhaug, M. Nyakas, K. T. Hagene, K. Holmsen, S. Aamdal, S. Kaasa, T. K. Guren, J. A. Kyte
Summary: This study reports on the health-related quality of life (HRQL) of real-world patients receiving ipilimumab, a checkpoint inhibitor, and evaluates the prognostic value of patient-reported outcome measures. The results show that HRQL significantly deteriorated during treatment with ipilimumab and that combining HRQL outcomes with objective risk factors can provide additional prognostic information for clinical decision making.
Article
Medicine, General & Internal
Alexander S. Watson, Siddhartha Goutam, Igor Stukalin, Benjamin W. Ewanchuk, Michael Sander, Daniel E. Meyers, Aliyah Pabani, Winson Y. Cheung, Daniel Y. C. Heng, Tina Cheng, Jose G. Monzon, Vishal Navani
Summary: This study examines the association between immune-related adverse events (irAEs) and survival in patients with metastatic melanoma, particularly those receiving combination immune checkpoint blockade (ICB).
Article
Oncology
E. L. Looman, P. F. Cheng, J. Lai-Kwon, L. Morgan, M. Wakkee, R. Dummer, F. Dimitriou
Summary: This study investigated the long-term symptom burden and impact on health-related quality of life of advanced melanoma patients treated with ICIs. The results showed that about 30% of patients reported long-term physical and emotional functioning issues, but overall health and quality of life were good.
Article
Oncology
Charlotte Nuebel, Teresa Amaral, Ulrike Leiter, Lukas Flatz, Andrea Forschner
Summary: The combined immune checkpoint inhibition with ipilimumab 1 mg/kg and nivolumab 3 mg/kg is an equally effective but better-tolerated therapy regimen for patients with metastatic melanoma, as supported by the results of the CheckMate 511 study.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Ming-Wei Kao, Yao-Hung Kuo, Kun-Chou Hsieh, Ching-Tai Lee, Shih-Chi Wu, Wen-Chi Yang
Summary: For patients with unresectable esophageal squamous cell carcinoma (SCC), combination therapy of nivolumab and chemotherapy demonstrates a better overall response rate and longer overall survival compared to chemotherapy alone or with radiotherapy. The expression of PD-L1 in esophageal cancer is associated with poor prognosis. Nivolumab with chemotherapy provides a more effective treatment option with fewer adverse effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Vincent T. Ma, Alahendra A. Chamila Perera, Yilun Sun, Merna Sitto, Jessica J. Waninger, Govind Warrier, Michael D. Green, Leslie A. Fecher, Christopher D. Lao
Summary: In patients with advanced melanoma, responses after 1 and 2 doses of I/N were associated with decreased risk of progression and/or death, with better PFS and OS compared to progressive disease (PD). However, there was no significant difference in survival outcomes between patients who received 1 or 2 doses compared to 3 or 4 doses of I/N for PFS and OS.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Daniel Roessler, Osman Oecal, Alexander B. Philipp, Daniel Markwardt, Stefan Munker, Julia Mayerle, Leonie S. Jochheim, Katharina Hammer, Christian M. Lange, Andreas Geier, Max Seidensticker, Florian P. Reiter, Enrico N. De Toni, Najib Ben Khaled
Summary: This retrospective study demonstrates that the combination of ipilimumab and nivolumab can be effective and well-tolerated after the failure of prior ICI-based combination therapies in patients with advanced HCC.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Sara J. Schonfeld, Margaret A. Tucker, Eric A. Engels, Graca M. Dores, Joshua N. Sampson, Meredith S. Shiels, Stephen J. Chanock, Lindsay M. Morton
Summary: In this cohort study of older adults with melanoma, ICIs were associated with autoimmune-related AEs and other immune-related AEs.
Article
Oncology
Helene Salaun, Leanne de Koning, Mathilde Saint-Ghislain, Vincent Servois, Toulsie Ramtohul, Agathe Garcia, Alexandre Matet, Nathalie Cassoux, Pascale Mariani, Sophie Piperno-Neumann, Manuel Rodrigues
Summary: Although the combined PD-1/CTLA-4 inhibition therapy with nivolumab/ipilimumab does not improve clinical outcomes compared to other therapies, it is more toxic and should be considered as an option rather than a standard treatment for metastatic uveal melanoma patients.
Article
Oncology
L. Susok, S. Said, D. Reinert, R. Mansour, C. H. Scheel, J. C. Becker, T. Gambichler
Summary: The pan-immune-inflammation value (PIV) and systemic immune-inflammation index (SII) in patients with cutaneous melanoma (CM) under immune checkpoint inhibitor (ICI) therapy do not seem to be significant predictors for clinical outcome measures of CM patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Pawel Sobczuk, Huber Batruk, Paulina Wojcik, Krzysztof Iwaniak, Katarzyna Kozak, Piotr Rutkowski
Summary: The current landscape of phase II studies in soft tissue sarcomas (STS) is analyzed in this study, and the impact of statistical design on the results is evaluated. The study finds high heterogeneity in the design of STS phase II trials, mainly in terms of primary endpoints and hypotheses used for sample size calculation. There is a need for standardization that takes into account factors associated with the rarity of the disease, outcomes detected in previous trials and real-life studies, and specific characteristics of new therapeutic agents.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Piotr Rutkowski, Sylvie Bonvalot
Article
Oncology
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long
Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jason A. Chesney, Antoni Ribas, Georgina Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari VanderWalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen Gogas
Summary: In this phase III study, the combination of T-VEC and pembrolizumab did not significantly improve progression-free survival or overall survival in patients with advanced melanoma. These findings indicate that this combination therapy is not effective in this patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Alexander C. J. van Akkooi, Dirk Schadendorf, Alexander M. M. Eggermont
Summary: Sentinel lymph node biopsy (SLNB) was introduced in the 1990s to identify patients who may benefit from completion lymph node dissection. SLNB staging has been found to be the best for staging melanoma. Adjuvant systemic therapy and biomarkers are emerging, which might reduce the need for SLNB staging in the future.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Dermatology
Jan-Malte Placke, Delphine Mertens, Alpaslan Tasdogan, Eleftheria Chorti, Dirk Schadendorf, Selma Ugurel, Alexander Roesch, Ingo Stoffels, Joachim Klode
Summary: This study demonstrates that multispectral optoacoustic tomography (MSOT) can differentiate between benign and malignant lymphadenopathy by measuring the levels of oxyhemoglobin and deoxyhemoglobin in lymph nodes. It offers a noninvasive approach to avoid unnecessary lymph node biopsies and surgeries.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Editorial Material
Biochemistry & Molecular Biology
Claus Garbe, Reinhard Dummer, Teresa Amaral, Rodabe N. Amaria, Paolo A. Ascierto, Elizabeth M. Burton, Brigitte Dreno, Alexander M. M. Eggermont, Axel Hauschild, Christoph Hoeller, Roland Kaufmann, Celeste Lebbe, Mario Mandala, Alexander M. Menzies, David Moreno, Olivier Michielin, Paul Nathan, Sapna P. Patel, Caroline Robert, Dirk Schadendorf, Paul C. Lorigan, Richard A. Scolyer, Hussein A. Tawbi, Bart A. van de Wiel, Christian Blank, Georgina V. Long
Summary: Individuals with cutaneous melanoma who receive neoadjuvant immunotherapy demonstrate significant improvement, which should be included in standard care.
Article
Oncology
Sebastian Bauer, James Larkin, F. Stephen Hodi, Frank Stephen, Ellen H. W. Kapiteijn, Gary K. K. Schwartz, Emilano Calvo, Padmaja Yerramilli-Rao, Sophie Piperno-Neumann, Richard D. D. Carvajal
Summary: The combination of PKC inhibitor sotrastaurin and MEK inhibitor binimetinib causes substantial gastrointestinal toxicity in patients with metastatic uveal melanoma, but stable disease is observed in a significant proportion of patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
J. B. A. G. Haanen, J. Larkin, T. K. Choueiri, L. Albiges, B. I. Rini, M. B. Atkins, M. Schmidinger, K. Penkov, E. Michelon, J. Wang, M. Mariani, A. di Pietro, R. J. Motzer
Summary: This study reports updated data from the phase III JAVELIN Renal 101 trial comparing avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. The results demonstrate improved overall survival and progression-free survival with avelumab plus axitinib compared to sunitinib, both in the overall population and in different risk groups. However, further follow-up is needed as the data are not yet complete.
Article
Oncology
Caroline A. Gjorup, Ines Pires da Silva, Linda Martin, Jonathan R. Stretch, Richard A. Scolyer, Georgina Long, Angela Hong
Summary: Two cases of primary desmoplastic melanoma of the nose were successfully treated with anti-PD-1 checkpoint inhibitor and radiation therapy, which provided good outcomes and cosmetic results. This suggests that PD-1 blockade and radiation therapy can be a safe alternative option for desmoplastic melanoma where surgery is morbidly disfiguring.
Review
Oncology
Monika Dudzisz-Sledz, Monika Kondracka, Monika Rudzinska, Agnieszka E. Zajac, Wiktoria Firlej, Dorota Sulejczak, Aneta Borkowska, Bartlomiej Szostakowski, Anna Szumera-Cieckiewicz, Jakub Piatkowski, Piotr Rutkowski, Anna M. Czarnecka
Summary: Mesenchymal chondrosarcoma (MCS) is a rare subtype of chondrosarcoma with a poor prognosis. The pathology and therapeutic options for MCS are still unknown due to its low incidence. Potential role of PDGF/PPI3K/AKT, PKC/RAF/MEK/ERK, and pRB pathways, and BCL2 overexpression have been reported in the pathogenesis of MCS. This review summarizes the current knowledge about MCS diagnosis and treatment options, including immunological and molecular biomarkers, prognostic and predictive factors. The novel trends in targeted therapies and ongoing clinical trials using protein kinase inhibitors and DR5 agonists are discussed as possible future focus in MCS treatment studies.
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Meeting Abstract
Oncology
Paul D. Nathan, Jennifer Allison, Natalie Charnley, Agnieszka Michael, Kathryn Moore, Anand Sharma, Bhupinder Klair, Valerie Perrot, James Larkin
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Biochemistry & Molecular Biology
Bryndis Yngvadottir, Avgi Andreou, Laia Bassaganyas, Alexey Larionov, Alex J. Cornish, Daniel Chubb, Charlie N. Saunders, Philip Smith, Huairen Zhang, Yasemin Cole, James Larkin, Lisa Browning, Samra Turajlic, Kevin Litchfield, Richard S. Houlston, Eamonn R. Maher
EUROPEAN JOURNAL OF HUMAN GENETICS
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)